Immuno-Oncology Europe 2019
Discovery and Development of Monoclonal Antibodies Targeting Tumor Neo-Epitopes Presented by Dr. Philip Arlen President and CEO,...
Discovery and Development of Monoclonal Antibodies Targeting Tumor Neo-Epitopes Presented by Dr. Philip Arlen President and CEO,...
Dr. Philip M Arlen, will be representing Precision Biologics in the PLENARY KEYNOTE SESSION, PANEL DISCUSSION:...
Abstract Title: Phase 1 with expansion cohorts in a study of NEO-201 in adults with...
First international congress of BIOIMMUNOTHERAPY OF CANCER An International multidisciplinary meeting 12-13-14 APRILE 2019 REGGIO CALABRIA ITALY Palazzo della Provincia, Sala...
Mechanisms of action of a neoantigen-targeting antibody NEO-201 AACR Annual Meeting - March 30-April 4 2019...
The Discovery and Development of Novel Monoclonal Antibody, NEO-201 Targeting a Novel Neoantigen Philip M. Arlen,...
Clinical trial tests safety and dosing of NEO-201 antibody in patients with advanced cancer NIH 11/01/2018 Patients...
The neoantigen-targeting antibody NEO-201 enhances NK cell-dependent killing of tumor cells through blockade of the...
Dr. Philip Arlen to Speak at Immunotherapy Progress and Clinical Treatments December 5-7, 2017 in San...
Dr. Philip Arlen to Speak at World Vaccine Congress Europe Topic: Targeting cancer neoantigens: A promising source...